The thalamus and multiple sclerosis
Modern views on pathologic, imaging, and clinical aspects
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received March 29, 2012
- Accepted August 6, 2012
- First Published January 7, 2013.
Author Disclosures
- Alireza Minagar, MD,
- Michael H. Barnett, MD, PhD,
- Ralph H.B. Benedict, PhD,
- Daniel Pelletier, MD,
- Istvan Pirko, MD,
- Mohamad Ali Sahraian, MD,
- Elliott Frohman, MD, PhD and
- Robert Zivadinov, MD, PhD
- Alireza Minagar, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Michael H. Barnett, MD, PhD,
1.Bayer, scientific advisory board2.Merck-Serono, scientific advisory board3.Novartis, scientific advisory board4.Sanofi-Aventis, scientific advisory board
NONE
1.Bayer, speaker honoraria2.Merck-Serono, speaker honoraria3.Novartis, speaker honoraria4.Sanofi-Aventis, speaker honoraria
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
1. NSW Government (Australia), Paul Brock Fellowship, 2012-2014
1. Multiple Sclerosis Research Australia, principal investigator 2009-2011
Nerve Research Foundation, The University of Sydney
NONE
NONE
NONE
NONE
NONE
NONE
- Ralph H.B. Benedict, PhD,
Biogen IdecActelionNovartisBayer
NONE
NONE
Editorial Board, Multiple Sclerosis, Neuropsychology, International Journal of MS Care, BMC Neurology
NONE
Brief Visuospatial Memory Test, Psychological Assessment Resources
NONE
NONE
NONE
NONE
NONE
Shire Inc, Biogen Idec, Accorda
NIH
NONE
National Multiple Sclerosis Society
NONE
NONE
NONE
NONE
NONE
Testified several times in personal injury trials
- Daniel Pelletier, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
CNS Imaging Consultant, LLC
NONE
NONE
NONE
I have received research grant support from Biogen-Idecover the past two years.
I receive research grant support from NIH/NINDSR01-NS062885 (PI).
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Istvan Pirko, MD,
NONE
NONE
NONE
Clinical Editor, Nanomedicine:NBM (Elsevier (www.nanomedjournal.com)Associate Editor, BMC Neurology
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NIH, R01NS058698, 2008-current
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Mohamad Ali Sahraian, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Elliott Frohman, MD, PhD and
NONE
NONE
TEVA, Biogen Idec, Acorda, Novartis, Bayer for speaking engagements.
NONE
NONE
NONE
TEVA, Biogen Idec, Acorda, Novartis for speaking engagements. 2009-2011
TEVA, Biogen Idec, Acorda, Novartis, Genzyme, Abbott for consulting. 2008-2012
TEVA, Biogen Idec, Acorda, Novartis. 2008-2012
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Robert Zivadinov, MD, PhD
NONE
NONE
Robert Zivadinov received personal compensation from TevaPharmacuticals, Biogen Idec, EMD Serono, Novartis andSanofi-Genzyme for speaking and consultant fees.
Section Editor for BMC Neurol for demyelinating diseasesfrom 2010.
NONE
NONE
NONE
NONE
Teva Pharmacuticals, Biogen Idec, EMD Serono, Novartis andSanofi-Genzyme.
NONE
The results from the CTEVD study led to the organizationof the IRB approved, (HSIRB #NEU2860310E) unblinded,open-label descriptive study into CCSVI that includespatients with either possible or definite MS. The purposeof this fee-for-service registry study is to enhanceutilization of data on venous anomalies that are obtainedon individuals who have sought information on CCSVI status.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- From the Department of Neurology (A.M.), Louisiana State University Health Sciences Center, Shreveport, LA; Department of Neurology (M.H.B.), Royal Prince Alfred Hospital, Sydney; Brain & Mind Research Institute (M.H.B.), University of Sydney, Australia; The Jacobs Neurological Institute (R.H.B.B., R.Z.) and Buffalo Neuroimaging Analysis Center, Department of Neurology (R.Z.), University at Buffalo, Buffalo, NY; Departments of Neurology and Diagnostic Radiology (D.P.), Yale University, New Haven, CT; Department of Neurology (I.P.), Mayo Clinic, Rochester, MN; Sina MS Research Center (M.A.S.), Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran; and Department of Neurology (E.F.), UT Southwestern Medical Center, Dallas, TX.
- Correspondence to Dr. Zivadinov: rzivadinov{at}bnac.net
Article usage
Cited By...
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Cutaneous α-Synuclein Signatures in Patients With Multiple System Atrophy and Parkinson Disease
Dr. Rizwan S. Akhtar and Dr. Sarah Brooker
► Watch
Related Articles
- No related articles found.
Alert Me
Recommended articles
-
Articles
Thalamic atrophy and cognition in multiple sclerosisM. K. Houtchens, R.H.B. Benedict, R. Killiany et al.Neurology, September 17, 2007 -
Article
Early CNS neurodegeneration in radiologically isolated syndromeChristina J. Azevedo, Eve Overton, Sankalpa Khadka et al.Neurology - Neuroimmunology Neuroinflammation, April 09, 2015 -
Views & Reviews
Gray matter involvement in multiple sclerosisIstvan Pirko, Claudia F. Lucchinetti, Subramaniam Sriram et al.Neurology, February 26, 2007 -
Articles
In vivo evidence of cerebellar atrophy and cerebral white matter loss in Huntington diseaseC. Fennema-Notestine, S. L. Archibald, M. W. Jacobson et al.Neurology, September 27, 2004